Can Diamox lower the eye pressure in glaucoma or glaucoma suspect patients who are receiving eye injections for wet age related macula degeneration?

Short-term intraocular pressure trends in high risk patients following intravitreal Ranibizumab (Lucentis) injections for Wet Age Related Macular Degeneration - Is there a role for systemic Acetazolamide (Diamox) in those with glaucoma? - LIEPS - Lucentis Injection Eye Pressure Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-023037-35-GB

Enrollment

Registered

2010-12-06

Start date

2011-05-05

Completion date

Unknown

Last updated

2012-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma and Glaucoma suspect MedDRA version: 14.1 Level: LLT Classification code 10006028 Term: Borderline glaucoma (glaucoma suspect) System Organ Class: 10015919 - Eye disorders MedDRA version: 14.1 Level: PT Classification code 10018304 Term: Glaucoma System Organ Class: 10015919 - Eye disorders

Interventions

Trade Name: Diamox (Acetazolamide) Product Name: Diamox (Acetazolamide) Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The sample group will include glaucoma and glaucoma suspect patients undergoing intravitreal injections for neovascular (wet) AMD at York Hospital. 1. Patients with neovascular (wet) AMD requiring Lucentis injections 2. Glaucoma or Glaucoma suspect 3. Written informed consent 4. Baseline pre injection Intraocular Pressure of less than 30 mmHg Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 0 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 24

Exclusion criteria

Exclusion criteria: 1. Baseline pre-injection IOP of 30 mmHg or higher 2. Unable to give written informed consent 3. Known allergy to sulphur containing drugs or acetazolamide 4. 18 years or younger 5. Marked kidney or liver disease/dysfunction 6. Supra-renal gland failure 7. Hypercholrcmic adcidosis 8. Hepatic cirrhosis 9. Pregnancy and pre-menopausal women 10. Concomitant use of other oral carbonic anhydrase inhibitors apart from acetazolamide

Design outcomes

Primary

Measure	Time frame
Main Objective: Does oral acetazolamide (Diamox) significantly reduce intraocular pressure in patients with glaucoma, who are receiving Lucentis injections for wet Age-related Macular Degeneration.;Secondary Objective: n/a;Primary end point(s): Primary endpoint is change in IOP at TO, T5, T10 and finally T30. A sample size calculation was based on a change of 9mmHg eye pressure in the intervention group versus no change in placebo group. ;Timepoint(s) of evaluation of this end point: TO minutes, T5 minutes, T10 minutes and finally T30 minutes.	—

Measure

Time frame

Main Objective: Does oral acetazolamide (Diamox) significantly reduce intraocular pressure in patients with glaucoma, who are receiving Lucentis injections for wet Age-related Macular Degeneration.;Secondary Objective: n/a;Primary end point(s): Primary endpoint is change in IOP at TO, T5, T10 and finally T30. A sample size calculation was based on a change of 9mmHg eye pressure in the intervention group versus no change in placebo group. ;Timepoint(s) of evaluation of this end point: TO minutes, T5 minutes, T10 minutes and finally T30 minutes.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026